Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 17/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 16/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.60 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.55 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.55 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387969 | 1.00 | ADORA2B (0.60) | ADORA2BADORA1ADORA2AADORA3PLK4 | |
| SCHEMBL21121497 | 0.93 | ADORA2B (0.60) | ADORA2BADORA1ADORA2AADORA3PLK4 | |
| SCHEMBL30291859 | 0.90 | ADORA2B (0.62) | ADORA2BADORA1ADORA2AADORA3PLK4 | |
| SCHEMBL21121160 | 0.90 | ADORA2B (0.62) | ADORA2BADORA1ADORA2AADORA3PLK4 | |
| SCHEMBL23067585 | 0.90 | ADORA2B (0.74) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL21153185 | 0.89 | ADORA2B (0.76) | ADORA2BADORA1ADORA2AADORA3PLK4 | |
| SCHEMBL21121530 | 0.88 | ADORA2B (0.76) | ADORA2BADORA1ADORA2AADORA3 | |
| SCHEMBL21153957 | 0.88 | ADORA2B (0.55) | ADORA2BADORA1ADORA2AADORA3PLK4 | |
| SCHEMBL242410 | 0.87 | ADORA2B (0.78) | ADORA2BADORA1ADORA2AADORA3PLK4 | |
| SCHEMBL21153955 | 0.87 | ADORA2B (0.65) | ADORA2BADORA1ADORA2AADORA3PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2024-05-14 | — | — | US | claimed |
| CN-111770926-B | Tricyclic compounds, compositions and pharmaceutical uses thereof | 因佩蒂斯生物科学有限公司 | 2023-07-21 | — | — | CN | claimed |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | claimed |
| US-11407758-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2022-08-09 | — | — | US | claimed |
| EP-3735413-B1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-07-06 | — | — | EP | claimed |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2021-03-11 | — | — | US | claimed |
| CN-111770926-A | Tricyclic compounds, compositions and medical uses thereof | 因佩蒂斯生物科学有限公司 | 2020-10-13 | — | — | CN | claimed |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2024-05-14 | — | — | US | disclosed |
| US-20240041889-A1 | COMBINATION THERAPY WITH ADENOSINE RECEPTOR ANTAGONISTS | TEON THERAPEUTICS INC (US) | 2024-02-08 | — | — | US | disclosed |
| CN-111770926-B | Tricyclic compounds, compositions and pharmaceutical uses thereof | 因佩蒂斯生物科学有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| US-11407758-B2 | Tricyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD. (IN) | 2022-08-09 | — | — | US | disclosed |
| EP-3735413-B1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2021-03-11 | — | — | US | disclosed |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2021-03-11 | — | — | US | disclosed |
| CN-111770926-A | Tricyclic compounds, compositions and medical uses thereof | 因佩蒂斯生物科学有限公司 | 2020-10-13 | — | — | CN | disclosed |
| WO-2019135259-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA1, ADORA2B | ADORA2B 3/4885ADORA1 2/4885ADORA2A 1/4885 |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA2B 4/4885ADORA1 3/4885ADORA2A 1/4885 |
| US-20240041889-A1 | COMBINATION THERAPY WITH ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | ADORA2B 2/4885ADORA1 3/4885ADORA2A 1/4885 |
| US-11407758-B2 | Tricyclic compounds, compositions and medicinal applications thereof | ADORA2A, ADORA3, ADORA1 | ADORA2B 4/4885ADORA1 3/4885ADORA2A 1/4885 |
| US-11981679-B2 | Tricyclic compounds, compositions and medicinal applications thereof | ADORA2A, ADORA1, ADORA2B | ADORA2B 3/4885ADORA1 2/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.